UCB SA (UCB.BR) Stock Fundamental Analysis
EBR:UCB - BE0003739530 - Common Stock
206.85 EUR
+2.25 (+1.1%)
Overall UCB gets a fundamental rating of 6 out of 10. We evaluated UCB against 50 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of UCB get a neutral evaluation. Nothing too spectacular is happening here. UCB is not overvalued while it is showing excellent growth. This is an interesting combination. This makes UCB very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year UCB was profitable.
UCB had a positive operating cash flow in the past year.
Each year in the past 5 years UCB has been profitable.
UCB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.75%, UCB is in the better half of the industry, outperforming 62.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of 13.76%, UCB is in line with its industry, outperforming 58.00% of the companies in the same industry.
The Return On Invested Capital of UCB (11.63%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for UCB is significantly below the industry average of 15.31%.
The 3 year average ROIC (4.35%) for UCB is below the current ROIC(11.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
The Profit Margin of UCB (19.45%) is better than 72.00% of its industry peers.
In the last couple of years the Profit Margin of UCB has remained more or less at the same level.
UCB has a Operating Margin of 26.58%. This is in the better half of the industry: UCB outperforms 72.00% of its industry peers.
UCB's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 73.38%, UCB is in the better half of the industry, outperforming 62.00% of the companies in the same industry.
In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UCB is creating some value.
Compared to 1 year ago, UCB has about the same amount of shares outstanding.
UCB has more shares outstanding than it did 5 years ago.
UCB has a better debt/assets ratio than last year.
2.2 Solvency
UCB has an Altman-Z score of 4.63. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
UCB's Altman-Z score of 4.63 is fine compared to the rest of the industry. UCB outperforms 70.00% of its industry peers.
The Debt to FCF ratio of UCB is 2.43, which is a good value as it means it would take UCB, 2.43 years of fcf income to pay off all of its debts.
UCB has a Debt to FCF ratio of 2.43. This is in the better half of the industry: UCB outperforms 72.00% of its industry peers.
UCB has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
UCB has a better Debt to Equity ratio (0.29) than 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 4.63 |
ROIC/WACC1.53
WACC7.61%
2.3 Liquidity
UCB has a Current Ratio of 1.35. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
UCB has a Current ratio (1.35) which is in line with its industry peers.
A Quick Ratio of 1.01 indicates that UCB should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.01, UCB is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
The Earnings Per Share has been decreasing by -0.86% on average over the past years.
Looking at the last year, UCB shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
UCB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.60% yearly.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
3.2 Future
The Earnings Per Share is expected to grow by 26.44% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.33% on average over the next years. This is quite good.
EPS Next Y50.88%
EPS Next 2Y39.49%
EPS Next 3Y35.29%
EPS Next 5Y26.44%
Revenue Next Year18.48%
Revenue Next 2Y15.85%
Revenue Next 3Y14.69%
Revenue Next 5Y12.33%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 32.22, the valuation of UCB can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as UCB.
Compared to an average S&P500 Price/Earnings ratio of 27.03, UCB is valued at the same level.
The Price/Forward Earnings ratio is 21.35, which indicates a rather expensive current valuation of UCB.
UCB's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.63. UCB is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.22 | ||
| Fwd PE | 21.35 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UCB is on the same level as its industry peers.
The rest of the industry has a similar Price/Free Cash Flow ratio as UCB.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.95 | ||
| EV/EBITDA | 16.39 |
4.3 Compensation for Growth
UCB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of UCB may justify a higher PE ratio.
UCB's earnings are expected to grow with 35.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.63
PEG (5Y)N/A
EPS Next 2Y39.49%
EPS Next 3Y35.29%
5. Dividend
5.1 Amount
UCB has a yearly dividend return of 0.49%, which is pretty low.
UCB's Dividend Yield is comparable with the industry average which is at 3.04.
Compared to an average S&P500 Dividend Yield of 2.32, UCB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.49% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
UCB pays out 19.82% of its income as dividend. This is a sustainable payout ratio.
UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y39.49%
EPS Next 3Y35.29%
EBR:UCB (9/5/2025, 1:15:00 PM)
206.85
+2.25 (+1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners38.65%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap40.23B
Analysts77.6
Price Target220.09 (6.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.49% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.81%
PT rev (3m)4.72%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.29%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.78%
Revenue NY rev (3m)1.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.22 | ||
| Fwd PE | 21.35 | ||
| P/S | 5.88 | ||
| P/FCF | 33.95 | ||
| P/OCF | 25.53 | ||
| P/B | 4.16 | ||
| P/tB | 37.01 | ||
| EV/EBITDA | 16.39 |
EPS(TTM)6.42
EY3.1%
EPS(NY)9.69
Fwd EY4.68%
FCF(TTM)6.09
FCFY2.95%
OCF(TTM)8.1
OCFY3.92%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.63
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROCE | 13.73% | ||
| ROIC | 11.63% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 58.2% | ||
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% | ||
| FCFM | 17.3% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexcg growth 3Y-25.87%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 61.48% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 16.4 | ||
| Cash Conversion | 64.17% | ||
| Profit Quality | 88.96% | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | 4.63 |
F-Score9
WACC7.61%
ROIC/WACC1.53
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y50.88%
EPS Next 2Y39.49%
EPS Next 3Y35.29%
EPS Next 5Y26.44%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year18.48%
Revenue Next 2Y15.85%
Revenue Next 3Y14.69%
Revenue Next 5Y12.33%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year142.1%
EBIT Next 3Y54.39%
EBIT Next 5Y36.53%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%